Oracle and Cerner: A Leap Forward in Safety

Webcasts

October 18th 2022 9 am CT |10 am ET | 3 pm BST | 4 pm CET Oracle’s market-leading safety software solutions provide highly powerful technology and algorithms for data mining. Combining Cerner Enviza’s real-world datasets containing de-identified, person-centric, longitudinal records offers a vast resource for expanding the potential of safety signaling.

Register Free: https://www.pharmexec.com/pe_w/safety

Event Overview:

How can life science companies apply safety signaling and real-world records to achieve better healthcare outcomes?

With Oracle’s recent acquisition of Cerner, new opportunities are emerging for this collaboration to improve the safety of medical products.

Oracle’s market-leading safety software solutions provide highly powerful technology and algorithms for data mining. Combining Cerner Enviza’s real-world datasets containing de-identified, person-centric, longitudinal records offers a vast resource for expanding the potential of safety signaling.


Key Learning Objectives:

  • The value of real-world data (RWD) and real-world evidence (RWE) to safety programs
  • An overview of how applications and data work together
  • The impact on post-marketing safety and adverse event monitoring
  • Innovative ideas for future applications in achieving better healthcare outcomes

Who Should Attend:

  • VPs and QPPVs of Safety
  • Safety evaluators
  • Safety IT professionals
  • Safety managers

Michael Fronstin
Global Head of Clinical Research and Consulting
Cerner Enviza an Oracle Company

Michael Fronstin is the Global Head of Clinical Research & Consulting and General Manager, Real-World Evidence (RWE) at Cerner Enviza. In his role, Michael incorporates patient centricity across Cerner Enviza’s portfolio, including but not limited to Real-World Qualitative research, Patient Preference and Non-interventional studies. Michael’s contributions to innovation initiatives, such as linking PROs and Patient Reported Data like Social Determinants of Health to Claims and EHR data, has led to unique patient insights. He previously worked at Kantar Health for more than 16 years in multiple roles, including as the Global Head of Innovation (RWE). In addition, Michael partners with Patient Advocacy Groups to build and leverage patient registries in rare diseases and has contributed to the development of RWE to support bringing new compounds to these patients. He holds an MBA in Healthcare Administration from the University of Miami Herbert Business School.


Susanne Faber
Director, Advanced Methodologies
Clinical Regulatory & Safety
Cerner Enviza an Oracle Company

Susanne is subject matter expert for non-interventional and real-world research studies at Cerner Enviza Clinical Regulatory and Safety. She has in-depth expertise in the development of innovative study designs and advises on study planning, conduction and procedural solutions. She has more than 25 experience in clinical and non-interventional research in a broad range of study designs, methodologies and indications. She has gained special expertise with regard to regulatory grade objectives and post-authorization safety studies (PASS). Susanne holds a university degree in Sociology from the University of Munich, Germany

Bruce Palsulich
Vice President of Product Strategy
Oracle Health Sciences

Bruce has over 30 years of experience in the healthcare and life sciences industry including 25 years in PV. At Oracle Health Sciences, he leads safety product strategy for Argus, the industry leader in case management; Empirica, the market leader in signal management; and Safety One Intake, Oracle Health Sciences’ first AI-powered solution.

Register Free: https://www.pharmexec.com/pe_w/safety